HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

HU 211 (HU 210)

structure given in first source; HU 211 is active & HU 210 is inactive as canibinoids; functional N-methyl-D-aspartate receptor blocker; RN given is for (6aS-trans)-isomer

Also Known As:

HU 210; 1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol; 1,1-dimethylheptyl-7-hydroxy-delta(6)-tetrahydrocannabinol; 11-OH-delta(8)-THC-DMH; 11-hydroxy-delta(8) -tetrahydrocannabinol-dimethylheptyl; 11-hydroxy-delta-8-DMH-THC; 11-hydroxymethyl-delta(8)-tetrahydrocannabinol-dimethylheptyl; 5'(1,1-dimethylheptyl)-7-hydroxyhexahydrocannabinol; 7-hydroxy-delta-6-tetrahydrocannabinoldimethylheptyl; HU 211, (6aR-trans)-isomer; HU-210; HU-211; HU210; dexanabinol; 6H-Dibenzo(b,d)pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS-trans)-

Networked: 101 relevant articles (11 outcomes, 22 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 58
- Hydrocarbons: 412
  - Terpenes: 260
    - Cannabinoids: 1257
      - Tetrahydrocannabinol: 997
        HU 211: 101

Experts

1.	Maslov, L N: 11 articles (09/2014 - 05/2001)
2.	Krylatov, A V: 10 articles (09/2014 - 06/2001)
3.	Lasukova, O V: 6 articles (01/2012 - 09/2003)
4.	Mechoulam, R: 5 articles (11/2012 - 11/2000)
5.	Pertwee, R G: 5 articles (07/2007 - 06/2001)
6.	Vaughan, Christopher W: 4 articles (01/2008 - 07/2005)
7.	Mitchell, Vanessa A: 4 articles (01/2008 - 07/2005)
8.	Lishmanov, Iu B: 3 articles (01/2012 - 05/2001)
9.	Ermakov, S Iu: 3 articles (07/2008 - 04/2006)
10.	Crawford, D: 3 articles (07/2008 - 04/2006)

Related Diseases

1.	Brain Injuries (Brain Injury) 01/01/2006 - "We sought to assess the safety and efficacy of dexanabinol, a synthetic cannabinoid analogue devoid of psychotropic activity, in severe traumatic brain injury. " 01/01/2006 - "Dexanabinol is safe, but is not efficacious in the treatment of traumatic brain injury." 01/01/2006 - "Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial." 03/01/2002 - "Dexanabinol as a treatment for traumatic brain injury: will another therapeutic promise be broken?" 01/01/2003 - "Dexanabinol (HU-211), a synthetic cannabinoid, is currently being assessed in clinical trials for traumatic brain injury and stroke. "
2.	Neuralgia (Stump Neuralgia) 12/01/2001 - "The aim of the present study was to investigate the effect of a potent cannabinoid agonist, HU210, on somatosensory transmission in a model of neuropathic pain. " 02/01/2006 - "In the present study, we compared the effect of a selective FAAH inhibitor, URB597, to that of a pan-cannabinoid receptor agonist HU210 in rat models of chronic inflammatory and neuropathic pain. " 02/01/2006 - "In contrast, HU210, but not URB597, reduced mechanical allodynia in the partial sciatic nerve-ligation model of neuropathic pain. " 05/01/2001 - "In the partial sciatic ligation model of neuropathic pain WIN55,212-2, CP-55,940 and HU-210 produced complete reversal of mechanical hyperalgesia within 3 h of subcutaneous administration with D50 values of 0.52, 0.08 and 0.005 mg kg(-1), respectively. " 07/15/2005 - "In the present study we found that systemic administration of the cannabinoid acid derivative 1',1'-dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid (ajulemic acid, IP-751) and the non-selective cannabinoid receptor agonist HU-210 reduced mechanical allodynia in a nerve-injury induced model of neuropathic pain and in the CFA-induced model of inflammatory pain. "
3.	Hypothermia 02/01/1995 - "These results suggest that the synthetic cannabinoid HU-210 acts in the preoptic area, probably via the brain cannabinoid receptor to induce hypothermia. " 01/01/2003 - "Four therapeutic strategies appear to be the most promising approaches currently in clinical trials for severe traumatic brain injury: a) the novel pharmacologic agent dexanabinol; b) hypertonic saline; c) mild hypothermia; and d) decompressive craniectomy. " 11/01/2003 - "New therapies currently under investigation include the use of dexanabinol, hypertonic saline solutions, moderate hypothermia, decompressive craniectomy, optimization of cerebral perfusion pressure, and reduction in cerebral microvasculature pressure (Lund therapy). " 05/01/2001 - "WIN55,212-2 (0.3-10 mg kg(-1)), CP-55,940 (0.03-1 mg kg(-1)) and HU-210 (0.001-0.03 mg kg(-1)) were all active in a 'tetrad' of tests consisting of tail-flick, catalepsy, rotarod and hypothermia following subcutaneous administration, with a rank order of potency in each of HU-210 > CP-55,940 > WIN55,212-2. " 02/01/1995 - "Intracerebral administration of IL-1 or PGE2 to rats pretreated with HU-210 caused a transient inhibition of the hypothermia. "
4.	Multiple Sclerosis 01/03/2000 - "The results suggest that dexanabinol may provide an alternative mode of treatment for acute exacerbations of multiple sclerosis (MS)." 01/03/2000 - "Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis." 01/01/2003 - "Dexanabinol is in clinical trials for traumatic brain injury (head injuries), glaucoma and mild cognitive impairment, and is being investigated preclinically for its potential in the treatment of multiple sclerosis. " 01/01/2007 - "Psychoactive and nonpsychoactive cannabinoid-based drugs such as Delta9-tetrahydrocannabinol, cannabidiol, HU-211, and ajulemic acid have been tested and found moderately effective in clinical trials of multiple sclerosis, traumatic brain injury, arthritis, and neuropathic pain. " 12/01/2000 - "Dexanabinol is a non-psychotropic cannabinoid NMDA receptor antagonist under development by Pharmos Corp for the potential treatment of cerebral ischemia, glaucoma, Alzheimer's disease, cardiac failure, head injury and multiple sclerosis (MS) [311522]; it is in phase III trials for traumatic brain injury (TBI) [388709]. "
5.	Brain Ischemia (Cerebral Ischemia) 01/01/1994 - "The novel tricyclic-terpenoid type cannabinoid, HU-211, was tested in gerbils and rats for protection against the effects of cerebral ischemia. " 05/18/2001 - "Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia." 01/15/1999 - "Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia." 12/01/1995 - "These results demonstrate the neuroprotective ability of HU-211 in focal cerebral ischemia as judged by neurological score, infarct size, and brain swelling. " 08/01/2003 - "Combination of dexanabinol and tempol in focal cerebral ischemia: is there a ceiling effect?"

Related Drugs and Biologics

1.	Cannabinoid Receptors (Cannabinoid Receptor)
2.	Tetrahydrocannabinol (THC)
3.	CB1 Cannabinoid Receptor (CB1 Receptor)
4.	ajulemic acid
5.	rimonabant
6.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
7.	Cannabinoids
8.	Win 55212-2 (WIN 55,212)
9.	Levodopa (L Dopa)
10.	Cannabidiol

Related Therapies and Procedures

1.	Decompressive Craniectomy
2.	Stents
3.	Analgesia
4.	Ligation
5.	Intravenous Injections